Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents

Vadadustat is an investigational oral hypoxia-inducible factor (HIF) prolyl-4-hydroxylase inhibitor to treat anemia due to chronic kidney disease (CKD). Some studies suggest that HIF activation promotes tumorigenesis by activating angiogenesis downstream of vascular endothelial growth factor, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalski, Heather, Hoivik, Debie, Rabinowitz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278385/
https://www.ncbi.nlm.nih.gov/pubmed/37158494
http://dx.doi.org/10.1177/01926233231168836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278385/
https://www.ncbi.nlm.nih.gov/pubmed/37158494
http://dx.doi.org/10.1177/01926233231168836

Ejemplares similares